Clinical case of mucocutaneous lymphonodular syndrome (Kawasaki disease)
https://doi.org/10.51922/2074-5044.2026.3.135
Abstract
Kawasaki syndrome (SC) is an acute systemic disease involving small and medium-sized arteries with the development of proliferative vasculitis. The main number of cases are children under 1 to 5 years of age, while the disease is extremely rare in children in the first months of life. Currently, there is an increase in IC all over the world. The problems of diagnosis of SC are associated with the rare occurrence and absence of pathognomonic symptoms and laboratory criteria of the disease, which leads to underdiagnosis of the latter. SC can pose a threat to the patient’s life and health not only in the acute period, but also after many years, which is associated with the risk of coronary artery aneurysms in patients who have not received adequate pathogenetic therapy, namely, the administration of intravenous immunoglobulins (IVIG). Meanwhile, timely diagnosis and administration of IVIG can reduce the risk of aneurysm formation from 25 % to 4 %. As is known, the presence of coronary artery aneurysms suggests life-threatening complications in the form of thrombosis and/or stenosis, which can lead to ischemia and sudden death at a young age. At the same time, the awareness of doctors of the therapeutic profile regarding the UK is insufficient. The article considers a case of Kawasaki disease in a three-month-old child, analyzes in detail the course of the pathological process.
About the Authors
I. A. LoginovaBelarus
Minsk
A. N. Bashlakova
Belarus
Minsk
A. A. Ustinovich
Belarus
Minsk
H. Y. Dolidovich
Belarus
Minsk
V. S. Khаtsko
Belarus
Minsk
T. G. Mozzhukhina
Belarus
Minsk
N. V. Sarkisyan
Russian Federation
Minsk
S. N. Pasynkova
Belarus
Minsk
References
1. Diagnosis, Treatment, and long-Term Management of Kawasaki Disease: A Scientific statement for Health Ptofessionals from the American Heart Assosiation / W. Mc Crindle [et al.] // Circulation. – 2017. – Vol. 135, № 17. – P. 927–999.
2. Guidelines for medical treatment of acute Kawasaki disease: report of the Cardic. Surgery Committee for Development // Pediatr. Int. – 2014. – Vol. 56, № 2. – P. 135–158.
3. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015–2016 / N. Makino [et al] // Pediatr. Int. – 2019. – Vol. 61, 4. – P. 397–403.
4. Clinic, diagnosis and treatment of Kawasaki syndrome (electronic resource): clinical recommendations. Moscow: All-Russian public organization Association of Pediatric Cardiologists of Russia, 2011. – 57 s. – Mode доступа: www.rodcb.ru/Klinic.rec/5.pdf. – Date of access 01/31/2026.
5. Litfullin, I. Ya. Litfullin // Bulletin of Modern Clinical Medicine. 2016. Vol. 9, No. 2. – Р. 52–60.
6. Kawasaki syndrome: modern approaches to diagnosis, treatment and patient management: an educational and methodological guide/ A. A. Galashevskaya, A. S. Pochkailo, I. V. Lazarchik – Minsk: «Professional publications», 2020. – 46 c.
7. Mucocutaneous lymphonodular syndrome (Kawasaki) (Kawasaki syndrome/disease) in children: Clin. recommendations. – M.: Union of Pediatricians of Russia, 2016. – 41 s
8.
Review
For citations:
Loginova I.A., Bashlakova A.N., Ustinovich A.A., Dolidovich H.Y., Khаtsko V.S., Mozzhukhina T.G., Sarkisyan N.V., Pasynkova S.N. Clinical case of mucocutaneous lymphonodular syndrome (Kawasaki disease). Military Medicine. 2026;(3):135-140. (In Russ.) https://doi.org/10.51922/2074-5044.2026.3.135
JATS XML